NCT04121273

GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC

Clinical Study of GPC3-targeted Chimeric Antigen Receptor T Cells fo Treating Advanced Hepatocellular Carcinoma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

Patients with hepatocellular carcinoma (a type of primary liver cancers) are enrolls in this study. The cancer has progressed after standard treatment, or the patient cannot receive regular treatment. Investigator made a gene called chimeric antigen receptor derived from an antibody that recognizes Glypican 3, a protein detected in in a large proportion of hepatocellular carcinoma. The gene will introduce into T cell from patient's blood to make them recognize and kill cancer cells. The aim of this study is to evaluate the efficacy, tolerance and safety of chimeric antigen receptor-modified T (CAR-T) cell targeting Glypican 3 for advanced hepatocellular carcinoma.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
BIOLOGICAL	CAR-T cell immunotherapy	Patients enrolled will recieve three different doses of the CAR-T cell every two weeks as follows: Dose 1: 1x10\^7/m2 Dose 2: 3x10\^7/m2 Dose 3: 1x10\^8/m2 The cell numbers are calculated according to CAR-positive T cells.

Timeline

• Start date: 2019-10-05
• Primary completion: 2021-10-01
• Completion: 2021-11-01
• First posted: 2019-10-09
• Last updated: 2021-03-03

Locations

1 site across 1 country: China